MARKET

IMMU

Immunomedics
IMMU
NASDAQ
Delisted
P/E
P/S
P/B
MARKET CAP
-47.6258
895.25
34.20
20,309,431,352.12
News
Financial
Releases
Corp Actions
Analysis
Profile
Top Healthcare Stocks for December 2020
These are the healthcare stocks with the best value, fastest growth, and most momentum for December 2020.
Investopedia · 11/19 18:03
Despite Setback, Iovance's Lifileucel Remains A Multibillion Dollar Prospect
Iovance Biotherapeutics, in an attempt to secure FDA-approval for their biologic, lifileucel, in advanced melanoma, was set back as the FDA requires some more information.This can't come to much of a surprise to investors, as Iovance's TIL therapy carries a complex manufacturing and delivery process compared to your typical drug.While the company figures BLA submission will be pushed back to 2021, investors need not lose sight of what is likely to be a blockbuster biologic once it clears all hurdles.Iovance remains an interesting speculative biotechnology investment as it continues to advance TIL therapy into the market.
Seekingalpha · 10/27 17:24
Were Hedge Funds Right About Crowding Into Immunomedics, Inc. (IMMU)?
While the market driven by short-term sentiment influenced by the accomodative interest rate environment in the US, virus news and stimulus talks, many smart money investors are starting to get cautious towards the current bull run since March and hedging or reducing many of their long positions. Some fund managers are betting on Dow hitting […]
Insider Monkey · 10/26 19:59
Gilead Sciences Closes Immunomedics Purchase
The two companies announced the $21 billion acquisition last month.
TheStreet.com · 10/23 15:47
Gilead Sciences Completes $21B Acquisition Of Immunomedics, Inc.
Gilead Sciences, Inc. (NASDAQ:GILD) today announced the completion of the previously announced transaction to acquire Immunomedics, Inc. (NASDAQ:IMMU) for approximately $21 billion in the aggregate. "We
Benzinga · 10/23 13:17
The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO
Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Oct. 22)
Benzinga · 10/23 11:26
Gilead Sciences Gets FDA Approval For Covid-19 Treatment Remdesivir
Investor's Business Daily · 10/22 22:35
Gilead’s Sales Will Slip Even With Remdesivir, Says Analyst
Citigroup analyst Mohit Bansal rates Gilead stock at Buy but lowered his target price to $75 from $80. He sees two more years of revenue decline.
Barrons.com · 10/22 13:58
More
Forecast
EPSBVPSCFPS
Actual (USD)
Estimate (USD)
Income StatementMore
Net IncomeTotal RevenueOperating Income
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
OperatingInvestingFinancing
Operating (USD)
YoY (%)
Learn about the latest financial forecast of IMMU. Analyze the recent business situations of Immunomedics through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 6 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average IMMU stock price target is 75.77 with a high estimate of 88.00 and a low estimate of 47.60.
EPS
Institutional Holdings
Institutions: 393
Institutional Holdings: 236.75M
% Owned: 102.42%
Shares Outstanding: 231.16M
TypeInstitutionsShares
Increased
89
37.09M
New
138
18.44M
Decreased
82
26.92M
Sold Out
0
0
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+2.89%
Pharmaceuticals & Medical Research
+1.72%
Key Executives
Chairman/Executive Director
Behzad Aghazadeh
Chief Financial Officer
Usama Malik
Chief Human Resource Officer
Kurt Andrews
Chief Accounting Officer
William Fricker
General Counsel/Secretary
Jared Freedberg
Executive Director
Scott Canute
Other
Bryan Ball
Other
Brendan Delaney
Other
Loretta Itri
Independent Director
Robert Azelby
Independent Director
Charles Baum
Independent Director
Barbara Duncan
Independent Director
Peter Hutt
Independent Director
Khalid Islam
  • Dividends
  • Splits
  • Insider Activity
No Data
Access Level 2 Advance
Nasdaq TotalView
for Free
Get Now

Webull offers kinds of Immunomedics stock information, including NASDAQ:IMMU real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, IMMU stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading IMMU stock methods without spending real money on the virtual paper trading platform.